Clinical Research Directory
Browse clinical research sites, groups, and studies.
Tc99m Sestamibi Molecular Breast Imaging
Sponsor: M.D. Anderson Cancer Center
Summary
This clinical trial studies technetium Tc-99m sestamibi molecular breast imaging in predicting tumor response in patients with locoregional breast cancer that has spread from where it began in the breast to surrounding normal tissue who are receiving neoadjuvant chemotherapy. Comparing results of diagnostic procedures, such as technetium Tc-99m sestamibi molecular breast imaging, done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Official title: Assessment of the Tumor Response to Neoadjuvant Chemotherapy in Women With Locoregional Invasive Breast Cancer Using Tc99m Sestamibi Molecular Breast Imaging: A Prospective Study
Key Details
Gender
FEMALE
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
96
Start Date
2015-06-15
Completion Date
2028-03-31
Last Updated
2026-03-09
Healthy Volunteers
No
Conditions
Interventions
Molecular Breast Imaging (MBI)
Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
Tc99m sestamibi
8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
Locations (1)
University of Texas MD Anderson Cancer Center
Houston, Texas, United States